A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Added to Chlorambucil Versus Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Jul 2018
At a glance
- Drugs Ofatumumab (Primary) ; Chlorambucil
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms COMPLEMENT 1
- Sponsors Genmab; GlaxoSmithKline; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 12 Jul 2018 This trial has been discontinued in France.
- 24 Apr 2018 Planned End Date changed from 1 Jul 2022 to 16 Jun 2022.
- 15 Feb 2018 The study has been discontinued in Italy.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History